Development of novel RvD1 analogues for osteoporosis therapy: mechanism of action and structure-activity relationships

用于骨质疏松症治疗的新型 RvD1 类似物的开发：作用机制和构效关系

• 批准号: 473051
• 负责人: Benderdour Mohamed
• 金额: $ 7.29万
• 依托单位: CIUSSS du Nord-de-l'Ile-de Montral - Hôpital Sacr Coeur
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-09-01 至 2023-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=473051&lang=en
• 关键词: Analogues; Apoptosis; Bone; Fpr2; Human; Mice; Osteoblast; Osteoclast; Osteoporosis; Rvd1

Osteoporosis (OP) is the most common age-related chronic disorders affecting bone tissue. Thus, more than 80% of fractures occur in patients aged 50 years and more are caused by OP. Approximately, 1.5 million Canadians aged 40 years and more say they have

骨质疏松症（OP）是影响骨组织的最常见的与年龄有关的慢性疾病。因此，超过80％的骨折发生在50岁的患者中，而更多的骨折是由OP引起的。大约有150万加拿大人40岁的加拿大人，更多的人说他们有